knowledge -WSS

knowledge

author：focus 2025-09-28 02:28:03 - browse：1927

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Ebola vaccine can save some who are already sick, per new study

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Readout Newsletter: Merck, J&J, and long Covid

Report cites 'urgent' need to recruit more diverse clinical trial participants

Elizabeth Holmes banned from government health programs

The surgeon had a dilemma only a Nazi medical text could resolve

eGenesis tests gene

knowledge

knowledge

explore

Medicare proposal to cover medical devices draws a mixed reaction

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Sports medicine is finally prioritizing gender equality

The tragedy of Johnson & Johnson’s Covid vaccine

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Cancer drug shortages should be causing more outrage

Readout Newsletter: Merck, J&J, and long Covid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why doctors need education on FDA device approval process

Wikipedia

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The surgeon had a dilemma only a Nazi medical text could resolve

Long Covid research funding gets a major boost from NIH

Wikipedia

explore

hotspot

entertainment